Skip to main content
Top
Published in: International Urology and Nephrology 1/2013

01-02-2013 | Nephrology – Original Paper

Serum osteocalcin levels are useful as a predictor of cardiovascular events in maintenance hemodialysis patients

Authors: Tetsuri Yamashita, Kazuhiro Okano, Yuki Tsuruta, Takashi Akiba, Kosaku Nitta

Published in: International Urology and Nephrology | Issue 1/2013

Login to get access

Abstract

Backgrounds

Osteocalcin (OC) is a known bone metabolic marker and a regulator of glucose and fat metabolisms. Although bone and energy metabolisms are known risk factors for cardiovascular disease (CVD) in hemodialysis (HD) patients, few studies have examined the correlation between OC and CVD. The purpose of this study was to investigate the impact of serum OC levels on the emergence of new CVD events in HD patients.

Methods

We designed a longitudinal, observational cohort study in which the study patients were divided into low- and high-serum OC groups based on a median serum OC level of 71.5 ng/ml.

Results

Cardiovascular disease events were observed in 29 of 126 patients (23.0 %). The number of cumulative CVD events in the low-serum OC group was significantly higher than that in the high-serum OC group, as evaluated by the Kaplan–Meier method (p = 0.0021, log-rank test). Multivariate Cox proportional hazards analysis demonstrated that a low level of serum OC is a significant predictor of a higher incidence of CVD events [hazard ratio, 2.925; 95 % confidence interval, 1.048–9.066; p = 0.0401] after adjustment.

Conclusion

Serum OC level is a significant, independent prognostic factor for CVD events in maintenance HD patients. OC may be useful in predicting new CVD events in HD patients.
Literature
1.
go back to reference Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990–1047PubMed Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990–1047PubMed
2.
go back to reference Stein GS, Lian JB (1993) Molecular mechanism mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 14:424–442PubMed Stein GS, Lian JB (1993) Molecular mechanism mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 14:424–442PubMed
3.
go back to reference Urena P, De Vernejoul MC (1999) Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55:2141–2156PubMedCrossRef Urena P, De Vernejoul MC (1999) Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55:2141–2156PubMedCrossRef
4.
go back to reference Malluche HH, Faugere MC, Fanti P, Price PA (1984) Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 26:869–874PubMedCrossRef Malluche HH, Faugere MC, Fanti P, Price PA (1984) Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 26:869–874PubMedCrossRef
5.
go back to reference Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhan Z, Kim JK, Mauvais Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469PubMedCrossRef Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhan Z, Kim JK, Mauvais Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469PubMedCrossRef
6.
go back to reference Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates β-cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci 105:5266–5270PubMedCrossRef Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates β-cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci 105:5266–5270PubMedCrossRef
8.
go back to reference Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, Sugimoto T (2011) Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 22:187–194PubMedCrossRef Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, Sugimoto T (2011) Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 22:187–194PubMedCrossRef
9.
go back to reference Yeap BB, Chubb SA, Flicker L, McCaul KA, Ebeling PR, Norman PE (2010) Reduced serum total osteocalcin is associated with metabolic syndrome in older men through its association with hyperglycemia, waist circumference and serum triglycerides. Eur J Endocrinol 163:265–272PubMedCrossRef Yeap BB, Chubb SA, Flicker L, McCaul KA, Ebeling PR, Norman PE (2010) Reduced serum total osteocalcin is associated with metabolic syndrome in older men through its association with hyperglycemia, waist circumference and serum triglycerides. Eur J Endocrinol 163:265–272PubMedCrossRef
10.
go back to reference Rostand SG, Drueke TB (1999) Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56:383–392PubMedCrossRef Rostand SG, Drueke TB (1999) Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56:383–392PubMedCrossRef
11.
go back to reference Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218PubMedCrossRef Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218PubMedCrossRef
12.
go back to reference Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793–1800PubMedCrossRef Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793–1800PubMedCrossRef
13.
go back to reference Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CS, Whellan D, Shama K (2007) A1c and survival in maintenance hemodialysis patients. Diabetes Care 30:1049–1055PubMedCrossRef Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CS, Whellan D, Shama K (2007) A1c and survival in maintenance hemodialysis patients. Diabetes Care 30:1049–1055PubMedCrossRef
14.
go back to reference Tsujimoto Y, Ishimura E, Tahara H, Kakiya R, Koyama H, Emoto M, Shoji T, Inaba M, Kishimoto H, Tabata T, Nishizawa Y (2009) Poor glycemic control is a significant predictor of cardiovascular events in chronic hemodialysis patients with diabetes. Ther Apher Dial 13:358–365PubMedCrossRef Tsujimoto Y, Ishimura E, Tahara H, Kakiya R, Koyama H, Emoto M, Shoji T, Inaba M, Kishimoto H, Tabata T, Nishizawa Y (2009) Poor glycemic control is a significant predictor of cardiovascular events in chronic hemodialysis patients with diabetes. Ther Apher Dial 13:358–365PubMedCrossRef
15.
go back to reference Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y (2002) Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13:1894–1900PubMedCrossRef Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y (2002) Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13:1894–1900PubMedCrossRef
16.
go back to reference Nakatsuka K, Miki T, Nishizawa Y, Tabata T, Inoue T, Morii H, Ogata E (1991) Circulating bone Gla-protein in end-stage renal disease determined by newly developed two-site immunoradiometric assay. Contrib Nephrol 90:147–154PubMed Nakatsuka K, Miki T, Nishizawa Y, Tabata T, Inoue T, Morii H, Ogata E (1991) Circulating bone Gla-protein in end-stage renal disease determined by newly developed two-site immunoradiometric assay. Contrib Nephrol 90:147–154PubMed
17.
go back to reference Maseters PW, Jones RG, Purves DA, Cooper EH, Cooney JM (1994) Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem 40:358–363 Maseters PW, Jones RG, Purves DA, Cooper EH, Cooney JM (1994) Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem 40:358–363
18.
go back to reference Rached MT, Kode A, Silva BC, Jung DY, Gray S, Onq H, Paik JH, DePinho RA, Kim JK, Karsenty G, Kousteni S (2010) FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation in osteoblasts in mice. J Clin Invest 120:357–368PubMedCrossRef Rached MT, Kode A, Silva BC, Jung DY, Gray S, Onq H, Paik JH, DePinho RA, Kim JK, Karsenty G, Kousteni S (2010) FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation in osteoblasts in mice. J Clin Invest 120:357–368PubMedCrossRef
19.
go back to reference Blayney MJ, Pisoni RL, Bragg-Gresham JL et al (2008) High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 74:655–663PubMedCrossRef Blayney MJ, Pisoni RL, Bragg-Gresham JL et al (2008) High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 74:655–663PubMedCrossRef
20.
go back to reference Epstein S, Traberg H, Raja R et al (1985) Serum and dialysate osteocalcin in hemodialysis and peritoneal dialysis patients and after renal transplantation. J Clin Endocrinol Metab 60:1253–1256PubMedCrossRef Epstein S, Traberg H, Raja R et al (1985) Serum and dialysate osteocalcin in hemodialysis and peritoneal dialysis patients and after renal transplantation. J Clin Endocrinol Metab 60:1253–1256PubMedCrossRef
21.
go back to reference Yeap BB, Chubb SAP, Flicker L, McCaul KA, Ebeling PR, Hankey GJ, Beilby JP, Norman PE (2012) Associations of total with all-cause and cardiovascular mortality in older men:the health in men study. Osteoporos Int 23(2):599–606 Yeap BB, Chubb SAP, Flicker L, McCaul KA, Ebeling PR, Hankey GJ, Beilby JP, Norman PE (2012) Associations of total with all-cause and cardiovascular mortality in older men:the health in men study. Osteoporos Int 23(2):599–606
22.
go back to reference Morishita T, Nomura M, Hanaoka M, Saruta T, Matsuo T, Tsukamoto Y (2000) A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in hemodialysed patients. Nephrol Dial Transplant 15:659–667PubMedCrossRef Morishita T, Nomura M, Hanaoka M, Saruta T, Matsuo T, Tsukamoto Y (2000) A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in hemodialysed patients. Nephrol Dial Transplant 15:659–667PubMedCrossRef
23.
go back to reference Frazao JM, Martins P (2009) Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens 18:303–307PubMedCrossRef Frazao JM, Martins P (2009) Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens 18:303–307PubMedCrossRef
24.
go back to reference Price PA, Williamson MK, Lothringer JW (1981) Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Bio Chem 256:12760–12766 Price PA, Williamson MK, Lothringer JW (1981) Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Bio Chem 256:12760–12766
25.
go back to reference Hwang YC, Jeong IK, Ahn KJ, Chung HY (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced β-cell function in middle-aged male subjects. Diabetes Metab Res Rev 25:768–772PubMedCrossRef Hwang YC, Jeong IK, Ahn KJ, Chung HY (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced β-cell function in middle-aged male subjects. Diabetes Metab Res Rev 25:768–772PubMedCrossRef
26.
go back to reference Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476PubMedCrossRef Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476PubMedCrossRef
27.
go back to reference Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–141PubMedCrossRef Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–141PubMedCrossRef
28.
go back to reference Rao M, Li L, Tighiouart H (2008) Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 23:2619–2628PubMedCrossRef Rao M, Li L, Tighiouart H (2008) Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 23:2619–2628PubMedCrossRef
Metadata
Title
Serum osteocalcin levels are useful as a predictor of cardiovascular events in maintenance hemodialysis patients
Authors
Tetsuri Yamashita
Kazuhiro Okano
Yuki Tsuruta
Takashi Akiba
Kosaku Nitta
Publication date
01-02-2013
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 1/2013
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-012-0156-6

Other articles of this Issue 1/2013

International Urology and Nephrology 1/2013 Go to the issue

Nephrology - Review

An update on uremic toxins

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.